[Advance subscriber edition]
New research opens path to block mutant JAK2
From the work of molecular biologist Stevan Hubbard and his colleagues, a new, detailed structure of the JAK2 molecule and its two integrated worlds opens new possibilities to block the mutated JAK2 activities…with the help of the pseudokinase.
And from the lab of Ross Levine, a co-discoverer of the JAK2 mutation, and his Novartis associate Thomas Radimerski, work with an experimental drug CHZ868 rolled back MPN symptoms, overcame the JAK2 resistance to Jakafi and reduced allele burden. This Type II generation may well have launched the second generation of JAK inhibitors.
It’s all in “Janus Unmasked” in the MPN Quarterly Journal Fall issue. http://mpnjournal.org/fall-2015/